Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPEASED
NCT05105919Phase 1Active, not recruiting
- Sponsor
- Montréal Heart Institute
- Start
- Aug 2021
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aspirin in type 2 diabetes mellitus (T2DM), sponsored by Montréal Heart Institute. Primary endpoint: Incomplete platelet aggregation inhibition by aspirin at 7 days. Started Aug 2021; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05105919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105919.